0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessToll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.
Melody Smith, Elena García-Martínez, Michael Pitter, Jitka Fučíková, Radek Špíšek, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi (2018). Trial Watch: Toll-like receptor agonists in cancer immunotherapy. , 7(12), DOI: https://doi.org/10.1080/2162402x.2018.1526250.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2018
Authors
8
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1080/2162402x.2018.1526250
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
